<DOC>
	<DOCNO>NCT01000636</DOCNO>
	<brief_summary>The aim study determine possible molecular change large scale gene expression profile treatment Metvix photodynamic therapy ( PDT ) actinic keratoses ( AK ) cancerised field renal transplant recipient .</brief_summary>
	<brief_title>Gene Expression Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy ( PDT )</brief_title>
	<detailed_description>Transplant recipient increase propensity develop multiple area field cancerisation subsequently develop multiple actinic keratoses , demonstrate increase transformation rate invasive squamous cell carcinoma ( SCC ) . The incidence cutaneous premalignant epithelial lesion actinic keratosis ( AK ) increase compare immunocompetent population mean occurrence 38 % 5 year immunosuppression , compare &lt; 5 % immunocompetent patient . Since development multiple AKs may portend possibility extensive cutaneous carcinogenesis , early aggressive treatment essential prevent progression invasive SCC . Although may occur single lesion , multiple actinic keratoses ( AKs ) commonly present area chronic actinic damage ( field AKs field cancerisation ) . The concept `` field cancerisation '' suggest clinically normal appear skin around AKs provide basis clonal expansion genetically alter neoplastic cell . This call sub-clinical AK lesion . In study , whole target area define investigator treat Metvix PDT : mean lesion sub-clinical lesion expose Metvix PDT . Biopsies perform region : lesional peri-lesional one . This allow u compare pre post treatment molecular change occur region evaluate Metvix PDT act sub-clinical lesion .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>Renal transplant history immunosuppression 5 15 year , Presenting least 4 discrete AK lesion , mild moderate , either face , scalp , forearm chest . At risk term precaution , warning , contraindication refer package insert Metvix® , AK lesions clinically atypical suspicious malignancy target field , Any follow topical treatment within specify washout period Screening : 5FU , Imiquimod , Diclofenac sodium : 3 month , Cryotherapy : 3 month , PDT : 3 month , Other less common AK treatment : 3 month . Systemic retinoids within last month prior Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Renal transplant patient</keyword>
	<keyword>Actinic Keratoses</keyword>
	<keyword>Metvix PDT</keyword>
	<keyword>Field cancerisation</keyword>
	<keyword>Gene expression</keyword>
</DOC>